Relay
Relay
Close
  • Who We Are
    • About
    • Approach
    • Our Team
  • Dynamo Platform
    • Integration of Tools
    • Motion-Based Drug Design
  • Our Science
    • Pipeline
    • Publications
  • Patients
  • Investors & Media
    • News & Events
    • Stock Information
    • Corporate Governance
    • ESG
    • Investor Resources
  • Careers
    • Culture & Benefits
    • Open Positions
Instagram

399 Binney Street, 2nd Floor

Cambridge, MA 02139

info@relaytx.com
(617) 370-8837
Publications

First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3Kα inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer

Download

Discovery and Characterization of the Potent, Allosteric SHP2 inhibitor GDC-1971 for the Treatment of RTK/RAS Driven Tumors

Download

RLY-2608: the first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models

Download

First Results of RLY-4008, a Potent and Highly Selective FGFR2 Inhibitor in a First-in-Human Study in Patients with FGFR2-Altered Cholangiocarcinoma and Multiple Solid Tumors

Download

Discovery and characterization of RLY-2608, the first allosteric, mutant, and isoform-selective inhibitor of PI3Kα

Download

First-in-human study of the highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors

Download

RLY‑4008, a Novel Precision Therapy for FGFR2‑Driven Cancers Designed to Potently and Selectively Inhibit FGFR2 and FGFR2 Resistance Mutations

Download

  • Who We Are
  • Our Team
  • Dynamo Platform
  • Our Science
  • Patients
  • Investors & Media
  • Careers
  • Contact
Relay Therapeutics logo

Relay Therapeutics

399 Binney Street, 2nd Floor

Cambridge, MA 02139

info@relaytx.com
(617) 370-8837
Twitter logo
LinkedIn logo
Instagram logo
© Relay Therapeutics 2022
Privacy Policy Terms of Use